Cargando…

Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights

Acute myeloid leukemia (AML) is a type of leukemia with a poor prognosis and survival characterized by abnormal cell proliferation and differentiation. Despite advances in treatment, AML still has a low complete remission rate, particularly in elderly patients, and recurrences are frequently seen ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Zalpoor, Hamidreza, Bakhtiyari, Maryam, Akbari, Abdullatif, Aziziyan, Fatemeh, Shapourian, Hooriyeh, Liaghat, Mahsa, Zare-Badie, Zahra, Yahyazadeh, Sheida, Tarhriz, Vahideh, Ganjalikhani-Hakemi, Mazdak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620650/
https://www.ncbi.nlm.nih.gov/pubmed/36316776
http://dx.doi.org/10.1186/s12964-022-00956-7
Descripción
Sumario:Acute myeloid leukemia (AML) is a type of leukemia with a poor prognosis and survival characterized by abnormal cell proliferation and differentiation. Despite advances in treatment, AML still has a low complete remission rate, particularly in elderly patients, and recurrences are frequently seen even after complete remissions. The major challenge in treating AML is the resistance of leukemia cells to chemotherapy drugs. Thus, to overcome this issue, it can be crucial to conduct new investigations to explore the mechanisms of chemo-resistance in AML and target them. In this review, the potential role of autophagy induced by FLT3-ITD and acid ceramidase in chemo-resistance in AML patients are analyzed. With regard to the high prevalence of FLT3-ITD mutation (about 25% of AML cases) and high level of acid ceramidase in these patients, we hypothesized that both of these factors could lead to chemo-resistance by inducing autophagy. Therefore, pharmacological targeting of autophagy, FLT3-ITD, and acid ceramidase production could be a promising therapeutic approach for such AML patients to overcome chemo-resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00956-7.